Senseonics Holdings Inc (NYSEAMERICAN:SENS) was the target of a large increase in short interest in the month of January. As of January 31st, there was short interest totalling 4,635,391 shares, an increase of 17.5% from the January 12th total of 3,946,300 shares. Based on an average daily volume of 667,199 shares, the days-to-cover ratio is presently 6.9 days. Currently, 9.6% of the shares of the stock are sold short.
In other Senseonics news, major shareholder Peter J. Barris sold 139,645 shares of the firm’s stock in a transaction dated Friday, December 8th. The stock was sold at an average price of $2.63, for a total value of $367,266.35. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 34.10% of the stock is owned by company insiders.
Several institutional investors and hedge funds have recently modified their holdings of the company. Bank of New York Mellon Corp bought a new stake in shares of Senseonics during the 3rd quarter valued at about $116,000. Perceptive Advisors LLC bought a new stake in shares of Senseonics during the 3rd quarter valued at about $160,000. Citadel Advisors LLC bought a new stake in shares of Senseonics during the 3rd quarter valued at about $194,000. Susquehanna International Group LLP bought a new stake in shares of Senseonics during the 2nd quarter valued at about $155,000. Finally, Raymond James Financial Services Advisors Inc. boosted its position in shares of Senseonics by 33.1% during the 3rd quarter. Raymond James Financial Services Advisors Inc. now owns 350,750 shares of the company’s stock valued at $1,119,000 after acquiring an additional 87,188 shares during the last quarter. Hedge funds and other institutional investors own 30.66% of the company’s stock.
Separately, Canaccord Genuity reiterated a “buy” rating on shares of Senseonics in a research report on Wednesday, November 1st.
Senseonics Holdings, Inc is a medical technology company. The Company focuses on the design, development and commercialization of glucose monitoring systems. The Company operates through glucose monitoring systems segment. It offers a continuous glucose monitoring (CGM) system, Eversense, which is designed an implantable CGM system designed to continually measure glucose levels in people with diabetes.
Receive News & Ratings for Senseonics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senseonics and related companies with MarketBeat.com's FREE daily email newsletter.